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Background: Multiple breast cancers may present with different clinical and biological characteristics. The data
indicate that multifocal (MF), multicentric (MC), and bilateral synchronous (BS) breast cancers (BC) are more
aggressive and have an equivalent or moderately poorer survival rate compared with unilateral cases. However, a
comparison of these multiple breast cancers has not been covered in the literature. The aim of this study was to
describe the histopathological characteristics of patients suffering from MF, MC, and BS breast carcinoma and to
compare their prognoses.
Methods: Retrospective data for MF, MC, and BS breast carcinoma patients treated in five different breast cancer
units in Turkey between 2003 and 2012 were collected. MF and MC cancers were defined as more than one lesion
in the same quadrant or in separate quadrants, respectively.
Results: There were 507 patients (271 MF, 147 MC, and 89 BS) treated in this time period. BS breast carcinoma
patients were younger than the other groups (44.83 ± 9.6, 47.27 ± 11.6, and 51.11 ± 11.8 years for BS, MF, and MC
breast carcinoma patients, respectively). MFBC and MCBC patients in this study were younger than the ages
reported in Western literature, but this result was similar to the ages reported in Eastern literature. The five-year survival
rates and recurrence rates were not statistically different among groups (P = 0.996 and P = 0.263, respectively).
According to univariate analyses, tumor size, histological grade, and lymph node status were statistically significant
factors that affected survival. However, only lymph node involvement was significant for survival according to
multivariate analyses.
Conclusions: The clinical significance of MF, MC, and BS breast cancers is still unclear and their influence on
prognosis is controversial. Disease-free and overall survival rates of BS breast cancers might be similar to MF and
MC breast cancers.
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Unilateral, multifocal, and multicentric breast cancers
have been of interest to oncology professionals for many
years, but their impact on prognosis and survival is con-
troversial [1]. While early clinical trials advocated mast-
ectomy for multifocal and multicentric tumors [2], the* Correspondence: huseyinkadioglu@gmail.com
1Department of General Surgery, Bezmialem Vakif University, Istanbul Adnan
Menderes Bulvarı Vatan Caddesi, 34093 Fatih/İstanbul, Turkey
Full list of author information is available at the end of the article
© 2014 Kadioğlu et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.recent literature suggests local recurrence rates do not
differ from unifocal tumors [3].
Bilateral synchronous breast cancer (BSBC) is a rare
entity with an incidence of between 1 and 3%. Surpris-
ingly, there has been no increase in BSBC incidence
since the 1980s [4]. However, its incidence has been re-
ported to be as high as 12% [5]. Different time intervals
have been used to define BSBC. In 1921, Kilgore defined
BSBC as a breast cancer in which both tumors are diag-
nosed at the same time [6]. Since 1921, different time in-
tervals have been used ranging from one month to fiveal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Hartman et al., who defined BSBC in 2007 as a tumor
diagnosed within 90 days of the first tumor [4].
Another dilemma regarding BSBC is the relationship
between tumors. Contradictory results on BSBC have
been published. Some authors have demonstrated si-
milarity in histologic subtype [8], tumor grade [9], and
hormone receptor status [10] between tumors, suggest-
ing a single-cell origin, but other authors have reported
different results [11]. Some authors believe that the tu-
mors are genetically different [12].
The survival effect of BSBC is also a dilemma for on-
cology professionals. While some reports advocate a worse
prognosis for BSBC, other reports do not suggest a worse
prognosis for BSBC.
According to the current literature, multifocal breast
cancer (MFBC) does not affect survival. Recent studies
have compared BSBCs with unilateral breast cancer, uni-
focal breast cancer, MFBC, and multicentric breast can-
cer (MCBC). We believe that this heterogeneity is the
cause of the differences reported in survival ratios, and
that tumors beginning from more than one focus should
be compared with other tumors beginning from more
than one focus.
The aim of this study was to compare the histopatho-
logical findings and survival of BSBC, MFBC, and MCBC
cases and to analyze the effect of molecular subtype on
survival.
Methods
The retrospective data for BSBC, MFBC, and MCBC pa-
tients treated in five different breast centers in Turkey
between 2003 and 2012 were collected.
All of these centers are university hospitals and have a
similar follow-up schedule for breast cancer based on
national comprehensive cancer network (NCCN) guide-
lines. The data were obtained from the oncology depart-
ments’ follow-up files of the patients.
The following patients were excluded from the study:
patients who were treated with neo-adjuvant chemothe-
rapy, patients who had a history of contralateral breast
cancer, patients who received chemotherapy or radio-
therapy for any kind of malignancy, patients who were
male; patients who were lost at follow-up, and patients
who were not seen by a medical professional in the pre-
vious six months.
Patients diagnosed with contralateral breast cancer in
the most recent 90 days were defined as BSBC. MFBC
was defined as tumors separated by normal breast tissue
in the same quadrant, and MCBC was defined as tumors
separated by normal breast tissue in different quadrants.
Multifocal and multicentric tumors were identified by ma-
croscopic examination of pathology specimens. In situ
components of the tumors were not added to the tumorsize. Tumors connected by in situ cancer were defined as
asunder foci. Also tumors which are closer than 5 mm to
each other are defined as satellite nodules.
A total of 507 patients met these criteria. Age at diag-
nosis, menopausal status, number of tumor foci (index
side for BSBC), tumor size (index side for BSBC), histo-
logical type (index side for BSBC), histological grade
(HG; defined using the Modified Bloom-Richardson grad-
ing system), lymphovascular invasion (LVI) status, lymph
node involvement, estrogen receptor status, progesterone
receptor status, HER2/neu status, stage, and molecular
subtype were recorded.
All five centers were using ultrasonography for the pre-
operative evaluation of the axillary, supra-clavicle, and in-
ternal mammary lymph nodes. All five centers were using
immunohistochemical methods to define HER2/neu sta-
tus up to year 2009; in situ hybridization techniques have
been in use since year 2009.
Estrogen receptor-positive patients with low Ki 67
levels (<14%), HER2/neu-negative, and low-grade tumors
were defined as luminal A. Estrogen receptor-negative
and/or patients with high Ki 67 levels (>20%) and HER2/
neu-negative tumors were defined as luminal B. HER2/
neu-positive patients were defined as HER2 type. Estrogen
receptor-, progesterone receptor-, and HER2/neu-negative
tumors were defined as triple negative. The histopatho-
logical parameters of the index side were recorded for
BSBC, and the type of the surgery was recorded as mast-
ectomy in the BSBC group if it was applied to any side.
The local recurrence and metastatic status at the final
follow-up were also recorded.Statistical analysis
The frequency and descriptive analyses of the cases were
recorded. The qualitative data were analyzed using Fisher’s
exact test, and the quantitative data were analyzed using
the Mann-Whitney U test. Survival analyses were con-
ducted using the Kaplan Meier test and the Cox multivari-
ate regression test, and logistic regression tests were used
for subgroup analyses. The data analysis was performed
using SPSS software (SPSS Statistics for Windows, Version
17.0. Chicago: SPSS Inc).Results
The total number of patients included in the study was
507. There were 89 patients in the BSBC group, 271
patients in the MFBC group, and 147 patients in the
MCBC group. Surprisingly, the MCBC patients were
significantly older than the other two groups. The mean
age in the MCBC group was 51.11 ± 11.9 years (range
of 29 to 83 years). The mean ages of the MFBC and
BSBC groups were 47.27 ± 11.63 years (range of 29 to
84 years) and 44.83 ± 9.67 years (range of 27 to 84 years),
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tients were postmenopausal (P <0.001).
The BSBC cases had more foci than the MFBC and
MCBC cases (mean focus number of 3.12 ± 1.46, 2.88 ±
1.54, and 2.3 ± 0.77, respectively; P <0.001). In addition,
the mean tumor size was larger in the BSBC patients
compared to that in the MFBC and MCBC patients
(55.88 ± 23.7 mm, 22.09 ± 12.0 mm, and 34.96 ± 20.5 mm,
respectively; P <0.001). The most common histolo-
gical type in all groups was invasive ductal carcinoma
(P = 0.001).
Compared to the other groups, the histological grade
was higher in the MCBC group (P <0.001), and the ma-
jority of the patients were lymphatic vascular invasion-
positive in the BSBC group (P <0.001).
There were no N0 patients in the BSBC group, and
most of the N3 patients were in the BSBC group. This
difference was statistically significant (P <0.001). A total
of 13 N-positive patients did not undergo axillary surgery
whilst their sentinel lymph node biopsy was positive; all
13 patients underwent additional axillary radiotherapy. No
local recurrences occurred in these patients.
Estrogen receptor status and progesterone receptor
status were also similar among the groups (P = 0.515 and
P = 0.193, respectively). Compared to the other patient
groups, there were more HER2/neu-positive tumors in
the MCBC patient group (P = 0.006).
Whilst we cannot obtain the detailed treatment regi-
mens we reported the obtainable treatment regimens for
three groups (89 patients (100%) for the BSBC group,
230 patients (84.8%) for the MFBC group and 100 pa-
tients for the MCBC group). Due to the heterogeneity
we did not apply statistical analyses.
The median follow-up time was 46.42 ± 23.2 months
(range of 1 to 108 months). However, for each group the
median follow-up was 49.63 ± 23.98, 44.29 ± 22.85, and
40.15 ± 19.92 months for MFBC, MCBC, and BSBC groups,
respectively.
Local recurrence and mortality were not different
among the groups (P = 0.263 and P = 0.996, respectively).
Five local recurrences occurred in BSBC group, three of
which were breast cancer recurrences and two of which
were axillary cancer recurrences. A total of 14 local re-
currences occurred in the MFBC group, eight of which
were breast cancer recurrences and six of which were
axillary cancer recurrences. Three local recurrences oc-
curred in MCBC group, two of which were breast cancer
recurrences and one of which was axillary cancer recur-
rence. Comparative analyses of these data are shown in
Table 1.
Local recurrence rates dependent on surgery type were
analyzed (5.6% for MFBC, 2.0% for MCBC, and 5.2% for
BSBC), and there was no significant difference between
surgery types (95.0 CI of 98.5 to 104.25; P = 0.369). Theselow local recurrence rates could be explained by careful
selection of patients for breast-conserving surgery. A
trustable clean surgical margin was defined as at least
2 mm at all five centers, and re-excisions were made to-
ward reaching these margins. Otherwise, a mastectomy
was performed.
Univariate analyses of survival indicated significant
differences in relation to histological type (P <0.001),
histological grade (P = 0.024), estrogen receptor status
(P <0.001), progesterone receptor status (P <0.001), lymph
node involvement (P = 0.025), and molecular subtype
(P <0.001). However, BSBC diagnosis, menopausal status,
lymphatic-vascular invasion, and HER2/neu status were
not statistically significant (P = 0.544, P = 0.092, P = 0.875,
and P = 0.104, respectively). Having a mastectomy was as-
sociated with a poorer prognosis (P <0.001).
There were not any statistically significant differences
in overall survival rates (the five-year survival rate was
82.7%, 86.9%, and 90.5% for the BSBC, MFBC, and MCBC
groups, respectively; P = 0.416) (Figure 1). The five-year
disease-free survival rate was 82.7%, 80.7%, and 75.5% for
the BSBC, MFBC, and MCBC groups, respectively (P =
0.024). When we compared the stage-dependent survival
analyses of the three groups, there was no significant dif-
ference among the mortality rates (95.0 CI of 0.731 to
15.191, P = 0.87; 95.0 CI of 0.661 to 5.240, P = 0.73; and
95.0 CI of 0.106 to 1.452, P = 0.63 for Stage I, II, and III,
respectively; Figure 2a, b, c).
Metastasis rates were different between the groups.
The highest ratio was in the MFBC group (18.4%, 27 out
of 271 patients) and the lowest ratio was in the BSBC
group (9%, 8 out of 89 patients, P = 0.04). We believe that
these ratios are the result of our small sampling size and
that this caused a statistical bias regarding the metastatic
ratios of this study.
We analyzed the usual prognostic parameters that were
statistically significant in Kaplan-Meier analyses using the
Cox multivariate regression test. Only lymph node status,
lymphatic-vascular invasion, and estrogen receptor status
had a statistically significant effect on survival (P = 0.006,
P = 0.027, and P = 0.41, respectively) (Table 2). Progester-
one receptor status alone did not have a statistically signi-
ficant effect on survival. Table 3 shows the univariate and
multivariate analyses data for the prognostic parameters.
Finally, we analyzed the survival effect of molecular
subtypes as luminal A, luminal B, triple negative, and HER2
type. While no survival difference was found between lu-
minal A and B patients (P = 0.142), mortality in triple-
negative patients was 5.11-fold greater than in luminal A
patients (95.0% CI of 2.06 to 9.48, P <0.001; Table 3).
Discussion
Multiple simultaneous tumor foci in the same breast are
referred to as multifocal or multicentric, but there is no
Table 1 Analyses of histopathological parameters and survival between the groups
BSBC MFBC MCBC P
(n = 89) (n = 271) (n = 147)
Age 44.83 ± 9.67 (27–84) years 47.27 ± 11.63 (19–84) years 51.11 ± 11.94 (29–83) years <0.001
Menopause Status <0.001
Premenopausal 56 (62.9%) 168 (62.0%) 60 (40.8%)
Postmenopausal 33 (37.1%) 103 (38.0%) 87 (59.2%)
Number of tumors (İndex side for BSBC) 3.12 ± 1.46 2.88 ± 1.54 2.3 ± 0.77 <0.001
Tumor size (mm) (İndex side for BSBC) 55.88 ± 23.7 22.0 ± 12.0 34.9 ± 20.5 <0.001
Histological type 0.001
Invasive ductal 75 (84.2%) 198 (73%) 134 (91.1%)
Mix 5 (5.6%) 23 (8.4%) 9 (6.1%)
Invasive lobular 6 (6.7%) 33 (12.1%) 4 (2.7%)
Others 3 (3.3%) 14 (6.1%) 0
Histological Grade (Modified Bloom Richardson) <0.001
I 10 (11.5%) 40 (15.0%) 34 (23.1%)
II 66 (75.9%) 113 (42.3%) 36 (24.5%)
III 11 (12.6%) 114 (42.7%) 77 (52.4%)
Lymphatic vascular invasion <0.001
Positive 68 (76.4%) 134 (49.4%) 77 (42.5%)
Negative 21 (23.6%) 137 (50.6%) 70 (47.6%)
Lymph node involvement <0.001
N0 0 128 (47.2%) 68 (46.3%)
N1 17 (19.1%) 83 (30.6%) 17 (11.6%)
N2 41 (46.1%) 40 (14.8%) 34 (23.1%)
N3 31 (34.8%) 20 (7.4%) 28 (19.0%)
Estrogen receptor status 0.515
Positive 53 (59.6%) 147 (54.8%) 87 (59.2%)
Negative 36 (40.4%) 124 (45.8%) 60 (40.8%)
Progesterone receptor status 0.193
Positive 69 (77.5%) 195 (72.0%) 98 (66.7%)
Negative 20 (22.5%) 76 (28.0%) 49 (33.3%)
HER2/neu status 0.02
Positive 8 (9.0%) 16 (5.9%) 24 (14.2%)
Negative 73 (90.1%) 255 (94.1%) 123 (83.7%)
Molecular subtypes 0.03
Luminal A 46 (51.7%) 135 (49.82%) 69 (46.9%)
Luminal B 16 (18.08%) 51 (18.8%) 19 (12.9%)
Triple negative 19 (21.3%) 69 (25.5%) 35 (23.8%)
HER2 type 8 (9.0%) 16 (5.9%) 24 (16.3%)
Type of surgery <0,001
BCS + SLN 0 132 (48.7%) 32 (21.8%)
BCS + AD 23 (25.8%) 105 (38.7%) 4 (2.7%)
MST + SLN 13 (14.6%) 11 (4.1%) 30 (20.4%)
MRM 53 (59.6%) 23 (8.5%) 81 (55.1%)
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Table 1 Analyses of histopathological parameters and survival between the groups (Continued)
Adjuvant treatment modalities Not applied
Chemotherapy 87 (97.7%) 141 (52.0%) 80 (54.4%)
Radiotherapy 89 (100%) 225 (83.0%) 75 (51.0%)
Endocrine therapy 60 (67.4%) 151 (55.7%) 85 (57.8%)
Targeted therapy 8 (9.0%) 12 (4.4%) 21 (14.2%)
Local recurrence 5 (5.6%) 14 (5.2%) 3 (2.0%) 0.263
Mortality 7 (7.9%) 22 (8.1%) 12 (8.2%) 0.996
AD: Axillary dissection; BCS: Breast conserving surgery; MRM: Modified radical mastectomy; MST: Mastectomy; SLN: Sentinel lymph node biopsy.
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in different quadrants are referred to as multicentric. Pa-
thologists define multiple simultaneous primary lesions
when there are two or more tumor foci without inter-
vening malignant tissue [14]. Pathologists define tumors
as multifocal when only one breast quadrant is involved,
and they define tumors as multicentric when two or more
quadrants are involved [14]. Radiologists do not have an
exact definition, but tumors are usually considered mul-
tifocal when the distance between the tumors is less
than or equal to 5 cm, and are considered multicen-
tric when the distance between the tumors is more
than 5 cm [15]. The estimated prevalence differs from
4 to 65%, and this variability is mainly due to the lack of
standardization in the gross examination and sampling of
breast specimens [16].Figure 1 Overall survival curve.BSBC is still a subject of debate for oncology profes-
sionals. The data regarding BSBC are sophisticated, and
the study results are confusing. We believe that the pa-
tient choice in the studies is the cause of this confusing
status. Synchronous and metachronous tumors are all
discussed similarly in these studies.
In addition, the comparisons of the groups are hetero-
geneous. Tumors that begin from more than one focus
(such as BSBC) are compared with unilateral and unifo-
cal tumors. At the same time, the biology of the tumors
beginning from more than one focus should be different.
The literature reports are not all based on the same
definition of BSBC [17]. A recent study evaluating 5292
patients in Germany found that differences in outcome
between synchronous and metachronous cancers depend
on time interval and that the optimal cut-off for the
Figure 2 Stage-dependent survival graphics of the groups.
a: Stage-dependent survival for Stage I patients. b: Stage-dependent survival
for Stage II patients. c: Stage-dependent survival for Stage III patients.
Table 2 Multivariate analyses for the effect of classical
histopathological parameters on overall survival between
the groups
P 95% CI OR
Histological grade 0.027 0.198-0.905 4.913
Estrogen receptor status 0.41 0.116-0.954 4.190
Progesterone receptor status 0.171 - -
Lymph node involvement 0.006 1.396-7.165 7.614
Molecular subtypes <0.001 2.74-13.55 23.63
CI: Confidence Interval; OR: Odds Ratio.
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the optimal definition of BSBC is cancers diagnosed sim-
ultaneously in both breasts or within three months (90
days) of diagnosis of the first tumor as described by
Hartman et al. [4]. For these reasons, it is difficult to
compare our results with the literature. We compared
our results with recent literature in which results for
BSBC were separately given for at least for 40 patients,
and the definition of BSBC was similar to ours. Only a
few studies have independently compared synchronous
and metachronous breast cancers, and these studies have
contradictory results [4,19-21].
Roder et al. concluded that the risk for BSBC increases
with age [21]. In general, other studies report a median
age older than 50 years [22]. A significant portion of our
BSBC patients were premenopausal (62.9%) with a me-
dian age that was younger (44.83 ± 9.67 years) than other
Western studies, yet the median age was similar to that
reported by Shi et al. (BSBC patient median age of 49 ±
15 years) [19]. Similarly, our MFBC and MCBC patients
were younger (the median age for MFBC and MCBC
was 47.27 ± 11.63 and 51.11 ± 11.94 years, respectively)
than the ages reported in Western literature, but this re-
sult was similar to the ages reported in Eastern literature
[23]. Recent literature evaluating 1492 consecutive breastTable 3 Univariate analyses for the effect of classical
histopathological parameters on overall survival between
the groups
P
Overall survival between groups 0.544




Estrogen receptor status <0.001
Progesterone receptor status <0.001
HER2/neu status 0.104
Lymph node involvement 0.045
Molecular subtypes <0.001
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patients are younger than 50 years [24]. Furthermore, an-
other study from Turkey evaluating MFBC and MCBC
has reported that 51.4% of the patients are premenopausal
[25]. These data suggest different biological behaviors of
breast cancer in different races.
In our study, the mean tumor size was larger than re-
ported in the literature for BSBC [19-22], yet all of these
reported studies included patients with neo-adjuvant
chemotherapy. Only one study from Italy excluded pa-
tients with neo-adjuvant chemotherapy, but the mean
tumor size in our study was larger than that reported by
Intra et al. [24].
The incidence of lobular histology is between 15 and
22% for BSBC in Western studies [20,22,26], but the in-
cidence was 6.7% in our study, which was similar to the
results reported by Eastern studies [23,25]. A large study
from British Columbia evaluating 25,320 breast cancer
patients reported a lobular histology incidence of 13.6%
[27]. The result for histological type was 12% in the stu-
dy of Cabioglu et al. [28]. This percentage is slightly less
than the ratio from British Columbia. Our cumulative
ratio for MFBC and MCBC was 9.6%, and this ratio was
slightly lower than both studies, but concordant with
Eastern studies [23].
A substantial percentage of the tumors had high histo-
logical grades. This result was similar to the literature in
which a histological grade of II or III was assigned to be-
tween 33.0 and 79.5% of BSBC patients and between
85.6 and 90.8% of MFBC and MCBC patients [20,25].
However, no studies are available that compare histo-
logical grade in BSBC to that in MCBC and MFBC.
As confirmed by NCCN guidelines, a higher histolo-
gical grade is an unfavorable factor for breast cancer.
Thus, we analyzed the survival effect of histological grade
by univariate and multivariate analyses. Histological grade
had a negative effect on survival in both analyses (univar-
iate analysis: P = 0.024; multivariate analysis: 95% CI of
0.198 to 0.905, P = 0.027).
The impact on the survival of these patients is a mat-
ter of discussion. Some publications conclude that BSBC
patients have worse prognoses [20,22,26], and other re-
ports do not refer to significant differences between uni-
lateral and BSBC [26]. Indeed, the largest study of BSBC
is a PhD thesis from Adelaide University (Australia)
[20]. McCaul [20] analyzed 4424 women with BSBC who
were diagnosed in the same month, and the results of
his thesis suggest that tumor burden should be taken
into consideration. He reported that bilateral stage I tu-
mors have a similar prognosis when compared with uni-
lateral stage I tumors, but that the survival of bilateral
stage II tumors is worse than unilateral stage II tumors.
However, a survival comparison of one side stage II and
one side stage I tumors with unilateral stage II tumorsshowed that BSBC patients have a similar survival rate.
In this study, we could not find a statistically significant
difference in the five-year overall survival, but the five-
year survival rates were lower for the BSBC group com-
pared to the other groups. Perhaps a new classification
in which the tumor burden of both breasts is included
should be made.
Gene expression profiling has led to a new molecular
classification of breast cancer with the triple-negative
subgroup having the worse prognosis. As predicted, the
triple-negative group had the worse prognosis in this
study.
The ratio of HER2/neu positivity is smaller than the
literature in the results of this study. We believe that the
cause of this difference could be the small sampling size.
Thus imaging modalities become more important at
the decision of BSBC-MFBC and MCBC, the role of
magnetic resonance imaging (MRI) is another redun-
dant point for the oncology specialists. Recent litera-
ture about the role of imaging modalities in the diagnosis
of BSBC suggests that a family history of breast can-
cer, a multifocal breast tumor, or the presence of an
invasive lobular carcinoma should be arguments for the
realization of a breast MRI to eliminate contralateral
malignancy [29]. Another prospective study from Turkey
that explores the utility of positron emission tomography/
computed tomography (PET/CT) scans to assess tu-
mor multifocality and multicentricity suggests that: “How-
ever, the specificity of the MR is rather poor, being less
than half that of PET/CT scans”. Thus PET/CT scan
data should be considered before aggressive surgery is
scheduled [30].
Only two case studies evaluating BSBC patients from
Turkey have been published (with a total of 20 patients)
[31,32]. However, larger studies evaluating multifocal
and multicentric breast cancers in Turkey are available
[25,28]. The number of patients reported in this study is
the largest series in Turkey. It is important to report the
status of BSBC patients in Turkey.
In conclusion, we need a common and accepted defin-
ition for BSBC. Prospective studies that include patients
who fit this description should be conducted to deter-
mine the survival statistics for BSBC. Staging of BSBC
should be investigated, and tumor burden should also be
taken into account.
The data for treatment regimens were insufficient,
which may affect the results of this study. In addition,
the follow-up period was too short, and long-term re-
sults could be different. Thus, this study can only give a
preliminary hypothesis regarding the short-term progno-
sis for tumors with multiple foci.
Of course the major limitation of this study is the fact
that it is a retrospective analysis, as well as the known
limitations and biases of the multicentric studies.
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In conclusion BSBC, MFBC, and MCBC had similar sur-
vival rates in this study. The multivariate analyses identi-
fied molecular subtypes and lymph node status as the
main factors that affected survival. However, results from
the literature are confusing because there are different
definitions and different survival results. Thus, a decision
about BSBC survival rates can be made only after a large
trial with a standardized definition of BSBC is conducted.
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